Merck and Eisai triplet therapy fails to improve survival in kidney cancer trial
Merck (NYSE:MRK) Eisai announced today that their Phase 3 LITESPARK-012 trial failed to meet its dual primary endpoints, a disappointing result for the pharmaceutical partners’ attempt to establish a new standard of care in first-line kidney cancer treatment.










